Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Omalizumab in Eosinophilic Gastroenteritis
NCT00084097Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in eosinophilic gastroenteritis (EGE), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2004; status: completed.
02
Drugs
omalizumab
03
Conditions
eosinophilic gastroenteritis (EGE)
Beyond the preview
Go deeper on NCT00084097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084097.